Press releases

Business Highlights during and after the third quarter of 2024

· Curasight designates brain cancer as initial indication for uTREAT
· Clinical Phase II trial of uPAR-PET in brain cancer patients
· Strong demand for rights issue resulted in heavy oversubscription
· Continued business development activities with industry players

Copenhagen, Denmark, 21 November 2024 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the interim report for the third quarter, and the first nine months, 2024. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.

Copenhagen, Denmark, 20 November 2024 - Curasight A/S ("Curasight" or "the Company" - TICKER: CURAS) hereby announces that the exercise price for the warrants of series TO2 (”TO2”), which were issued in connection with the directed issue and rights issue of units the Company executed earlier during 2024, has been set. The exercise price for TO2 has been set to DKK 11.50 per share and the exercise period commences on 21 November 2024.

Copenhagen, Denmark, 14 November 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CMO professor Andreas Kjær will present the company’s latest progress and strategy at HC Andersen Capital, BioStock Life Science Summit 2024 and Økonomisk Ugebrev Life Science Investor Conference

· New patent application related to uTREAT will extend patent protection until 2043
· Application adds several new alpha- and beta-emitters to protection under existing issued patents
· Application strengthens patent family for Curasight’s uPAR-targetting technology, aimed at improving cancer diagnosis (uTRACE) and treatment (uTREAT)

Copenhagen, Denmark, 13 November 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) announces today the publication of its international patent application for uTREAT®. The patent application is in addition to already granted patents covering the company’s peptide-based uPAR-targeting technology and if granted will extend patent protection to 2043.

· Brain cancer (high-grade glioma (HGG)) selected as first indication for uTREAT[®]
· Addresses a clear unmet medical need
· Clinical development plan established
· Clinical trial application (CTA) submission anticipated early Q1 2025
· First patient dosed with uTREAT late Q2 2025

Copenhagen, Denmark, 11 November 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) announces today that it has chosen brain cancer (high-grade glioma (HGG)) as the first indication for uTREAT[®] as a potential cancer therapeutic. The company aims to dose the first patient with uTREAT[®] end of Q2 2025.

Copenhagen, Denmark, 8 November 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CMO Andreas Kjær have been invited to present the company’s latest progress and strategy at Dansk Aktionærforening InvestorDagen in Copenhagen 11 November 2024

· Curasight’s radiopharmaceutical approach leverages the uPAR theranostic platform with the aim of providing improved diagnosis (uTRACE) and more gentle treatment (uTREAT) of certain types of cancers
· Data from the Phase II uTRACE trial is now published in full in the peer-reviewed journal EJNMMI Research

Copenhagen, Denmark, 7 November 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) announces today that the investigator-initiated phase II study using uPAR-PET in brain cancer has been published

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER DANISH LAW.

Copenhagen, Denmark, 11 October 2024 – Curasight A/S’s (“Curasight” or the “Company”) rights issue of units, with a subscription period that ended on 30 September 2024 (the “Rights Issue”), has now been registered with the Danish Business Authority (in Danish: Erhvervsstyrelsen) as a result of updated articles of association. Trading in paid subscribed units (“BTU”) will therefore cease and BTU will be replaced by warrants of series TO2 and series TO3. The last day of trading in BTU is 16 October 2024 and the record date is 18 October 2024. The first day of trading in warrants of series TO2 and TO3 is 17 October 2024.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE.

Copenhagen, Denmark, 3 October 2024 – The subscription period in Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) preferential rights issue of units consisting of warrants of series TO2 (”TO2”) and series TO3 (“TO3”) (the “Rights Issue”) ended on 30 September 2024. The Rights Issue was heavily oversubscribed by 17,299%. The majority of the rights issue (90% corresponding to 1,098,708 units) was subscribed to with unit rights and a further 209,410,287 units were subscribed to without unit rights. A formal decision on allocation is expected to take place today.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE.

Copenhagen, Denmark, 16 September 2024 – The subscription period in Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) rights issue of units consisting of warrants of series TO 2 (”TO2”) and series TO 3 (“TO3”) (the “Rights Issue”), with preferential right for the Company's existing shareholders begins today. The subscription period runs until 30 September 2024. The proceeds from the warrants issued through the recently executed directed issue and the Rights Issue combined are to be used to fund the advancement of Curasight's pipeline within the field of radiopharmaceuticals, enabling the parallel development of the Company's diagnostic uTRACE® platform and radioligand therapy uTREAT® platform, as well as support activities connected to the ongoing collaboration with Curium Inc. The transaction ensures strategic flexibility, with the full financing extending the cash runway into the second half of 2025. A prospectus is available via the Company's (www.curasight.com), Sedermera Corporate Finance AB's (www.sedermera.se) and Nordic Issuing AB's (www.nordic-issuing.se) websites. Subscription of units in the Rights Issue is made through each shareholder’s bank. For a Q&A document describing details on the Rights Issue and how to participate, please visit www.curasight.com.